THE WOODLANDS, Texas, Feb. 03, 2017 -- LGI Homes, Inc. (Nasdaq:LGIH) today announced 172 homes closed in January 2017, compared to 232 home closings in January 2016.
“Although January closings were down year over year, sales are off to a strong start in 2017 and demand for homeownership remains solid. Assuming that general economic conditions, including interest rates and mortgage availability, in the remainder of 2017 are similar to those in the fourth quarter of 2016, we believe we are on track to close more than 4,700 homes this year,” said Eric Lipar, the Company's Chief Executive Officer and Chairman of the Board.
As of the end of January 2017, the Company had 65 active selling communities.
About LGI Homes, Inc.
Headquartered in The Woodlands, Texas, LGI Homes, Inc. engages in the design, construction and sale of homes in Texas, Arizona, Florida, Georgia, New Mexico, Colorado, North Carolina, South Carolina, Washington and Tennessee. The Company has a notable legacy of more than 13 years of homebuilding operations, over which time it has closed over 16,000 homes. For more information about the Company and its new home developments, please visit the Company's website at www.LGIHomes.com.
Forward-Looking Statements
Any statements made in this press release that are not statements of historical fact, including statements about the Company's beliefs and expectations for 2017 home closings, are forward-looking statements within the meaning of the federal securities laws, and should be evaluated as such. For more information concerning factors that could cause actual results to differ materially from those contained in the forward-looking statements please refer to the "Risk Factors" section, including, without limitation, the risk factor entitled "Cautionary Statement about Forward-Looking Statements" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015 filed by the Company with the Securities and Exchange Commission ("SEC") on March 9, 2016 and similar sections in the Company's subsequent filings with the SEC. The Company bases these forward-looking statements on its current expectations, plans and assumptions that it has made in light of its experience in the industry, as well as its perceptions of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances and at such time. As you read and consider this press release, you should understand that these statements are not guarantees of future performance or results. The forward-looking statements are subject to and involve risks, uncertainties and assumptions and you should not place undue reliance on these forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Investor Relations Caitlin Stiles, (281) 210-2619 [email protected]


FDA Approves Mitapivat for Anemia in Thalassemia Patients
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 



